Skip to main content

Table 2 I-124 codrituzumab pharmacokinetics

From: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Dose Co observed %IA/L Co estimated %IA/L Vc (L) T1/2 delayed (h)a AUC based on fit (%IA × h/L) Clearance (ml/h) Vdss (L)
10 mg (n = 14) 32.9 ± 9.1 32.4 ± 9.2 3.399 ± 1.233 46.2 ± 12.58 1712 ± 438 61.8 ± 14.8 3.669 ± 1.281
2.5 mg/kg (total 130–240 mg) (n = 4) 35.3 ± 10.3 35.3 ± 10.5 3.033 ± 0.894 125.7 ± 129.3 3429 ± 1559 34.2 ± 15.4 2.924 ± 0.830
5 mg/kg (total 260–400 mg) (n = 3) 39.2 ± 5.24 37.3 ± 6.8 2.740 ± 0.464 99.7 ± 26.6 3956 ± 757 25.8 ± 4.5 3.504 ± 0.871
  1. aIn 14 studies, this represents the beta component of biexponential fit; in 7 studies, this represented the monoexponential fit. Fits were performed using SAAM software